EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Role of metabolites in drug-drug interactions

Nina Isoherranen

Drug Metabolism and Pharmacokinetics · 2026

DOI: 10.1016/j.dmpk.2025.101511 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2026. Verfasst von Nina Isoherranen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States. Electronic address: ni2@uw.edu. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme System, Cytochrome P-450 Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institutes of Health, University of Washington.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the publication of the metabolites in safety testing (MIST) guidance by the US FDA in 2009, there has been continuous interest and expansion in research aimed at predicting and characterizing circulating metabolites. Several systematic reviews and original research articles have been published to assess the role of metabolites in drug-drug interactions. Abundant circulating metabolites have been found to be common with classic cytochrome P450 (CYP) enzyme inhibitors and with new drugs in development. This has raised the need for better tools to predict significant circulating metabolites from preclinical data to streamline metabolite testing. This review summarizes the current recommendations for metabolite testing, evaluates the existing data on reversible and time-dependent inhibition of CYP enzymes by circulating metabolites, and explores the potential inhibition of drug transporters by circulating metabolites. The possible role of metabolites in induction of CYP enzymes is also discussed. The mathematical methods to incorporate multiple precipitants into risk assessment and quantitative prediction methods for inhibition and induction are summarized. Finally, the unique considerations regarding PBPK modeling of metabolites are discussed to highlight potential differences in the metabolite liver concentrations used in static versus more dynamic PBPK prediction methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 Enzyme SystemCytochrome P-450 Enzyme InhibitorsDrug InteractionsHumansPharmaceutical PreparationsAnimalsModels, Biological

Stichwörter der Autor:innen

Cytochrome P450Drug-drug interactionEnzyme inhibitionIn vitro to in vivo predictionsMetabolitePBPK modeling

Substanzen

Cytochrome P-450 Enzyme SystemPharmaceutical PreparationsCytochrome P-450 Enzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States. Electronic address: ni2@uw.edu.

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health
  • University of Washington
  • National Institute of General Medical Sciences

Zitieren

APA

Isoherranen, N. (2026). Role of metabolites in drug-drug interactions. Drug Metabolism and Pharmacokinetics. https://doi.org/10.1016/j.dmpk.2025.101511

Vancouver

Isoherranen N. Role of metabolites in drug-drug interactions. Drug Metabolism and Pharmacokinetics. 2026. doi:10.1016/j.dmpk.2025.101511

BibTeX
@article{Isoherranen2026,
  author = {Isoherranen, Nina},
  title = {Role of metabolites in drug-drug interactions},
  journal = {Drug Metabolism and Pharmacokinetics},
  year = {2026},
  doi = {10.1016/j.dmpk.2025.101511}
}
Kostenlos starten →